Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .
Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study.
OBJECTIVE The use of atypical antipsychotics ( AAPs ) for the treatment of unipolar and bipolar depression has been more and more frequently evaluated , and aripiprazole showed positive effects in the treatment of unipolar depression . However , no placebo-controlled studies of adjunctive aripiprazole for the treatment of bipolar depression have been performed yet . METHODS In this prospect i ve , double-blind ,  placebo-controlled  , r and omized trial , 23 in patients with bipolar depression according to DSM-IV criteria were included . Before r and omization , patients had to be on a constant mood stabilizer treatment with lithium or valproate for at least 1 week . After inclusion , all patients were openly treated with additional citalopram and with additional aripiprazole or placebo for 6 weeks . The primary outcome parameter was the reduction in depressive symptoms according to the Hamilton Depression Rating Scale ( HDRS ) within 6 weeks . RESULTS After 6 weeks of treatment , the HDRS score decreased in both groups . There was no significant difference between both the groups at any point of time with respect to the HDRS . CONCLUSIONS Derived from this small pilot study , adjunctive aripiprazole does not seem to be a promising strategy for the acute treatment of bipolar depression . However , this lack of additional benefit seems to stem from the already good effectiveness of the control group , namely the treatment with citalopram
Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .